About us
Browse:
Our mission
Leadership
Our story
Contact Moderna
tab3
We set out to change the world and make mRNA medicines a reality for humanity.
75
card, right
We’re making biotech history
Messenger RNA is not new technology, but we are discovering new ways to use it to treat and prevent illnesses and diseases. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform.
false
true
Our big moments
h2
2010
Moderna incorporates
h3
Moderna’s name combines the words "modified" and "RNA," which happens to contain the word "modern.”
2011
Operations started
h3
Moderna begins research into the production of mRNA medicines. Stéphane Bancel joins as founding CEO.
2014
Expansion
h3
New headquarters and labs open in Cambridge, Massachusetts.
2015
First human dose of flu vaccine
h3
Moderna initiates first-in-human dose of an mRNA vaccine (mRNA-1440), an H10N8 flu vaccine candidate.
2016
New lease signed
h3
Lease signed to build 200,000 sq ft GMP mRNA clinical manufacturing facility in Norwood, MA
2017
First human dose of multivalent vaccine
h3
Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease–human metapneumovirus (hMPV virus) and parainfluenza virus.
2018
New facility opens
h3
Moderna opens its state-of-the-art clinical development site in Norwood, MA.
2019
First antibody encoded by mRNA
h3
Moderna announces dosing of the first antibody encoded by mRNA in a clinical trial.
2020
Moderna concluded agreement with Ministry of Health of Singapore
h3
Moderna concluded an agreement with the Ministry of Health of Singapore to supply Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore during the pandemic
2020
CDC recommendations
h3
CDC recommends Moderna's Covid-19 vaccine for Americans over 18
2021
Singapore Health Sciences Authority (HSA) approves interim authorization of Moderna's COVID-19 vaccine for use
h3
Singapore Health Sciences Authority (HSA) has approved the interim authorization of its mRNA vaccine against COVID-19 (COVID-19 Vaccine Moderna) for use under the Pandemic Special Access Route (PSAR)
2022
Moderna receives full approval for COVID-19 vaccine by U.S. FDA
h3
The U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older in the U.S.
2022
Singapore Subsidiary
h3
Moderna expand footprint in Asia and sets up subsidiary in Singapore